Thymos Health
Your Myositis Journey

Still weak.
Still rashed. Still on high-dose steroids.
Still waiting for a real option.

You're not alone. This is how dermatomyositis and polymyositis are typically managed — and an honest look at what that journey costs, and what it leads to, over time.

1–10 adults per million are diagnosed with dermatomyositis — a genuinely rare disease.1
2021 is the year the first FDA-approved therapy for dermatomyositis finally arrived.2
79% IVIG response rate vs. 44% placebo in the pivotal ProDERM trial.3
60–80% is the 5-year survival range historically reported for PM/DM.4

How dermatomyositis / polymyositis is typically treated

Until 2021, there was no FDA-approved therapy for dermatomyositis at all — everything was used off-label, extrapolated from small, decades-old studies.

Mark where you are in your journey and we'll show you the full picture.

Step 1: Your rheumatologist starts you on High-Dose Prednisone
1mg/kg/day (or 40–60mg/day), tapered as creatine kinase (CK) normalizes over ~12 months
What your doctor says
"Your muscle enzymes are very elevated, and there's no controlled trial establishing an ideal steroid dose — but high-dose prednisone remains the universal first-line therapy."
Remains first-line despite no placebo-controlled trial ever conducted5
12-month taper is standard — a full year of steroid exposure
CK monitored every 3–4 weeks to guide tapering
Annual cost before insurance (generic) ~$100–$400
Providers seen before this was prescribed
How long were you on this?
What happened?
Your coinsurance for this drug
Your estimated annual out-of-pocket for this drug
$0
Steroid-sparing agent added once tapering begins
Step 2: As you taper, you add Methotrexate or Azathioprine
Steroid-sparing immunosuppressant added to allow steroid reduction and prevent relapse
What your doctor says
"Now that your CK is improving, we'll add a steroid-sparing drug so we can bring your prednisone dose down without your disease flaring back up."
22% relapse rate reported with drug withdrawal in one cohort6
5-year survival historically 60–80%, driven by overlap and malignancy risk4
Annual cost before insurance (generic) ~$150–$600
How long were you on this?
What happened?
Your coinsurance for this drug
Your estimated annual out-of-pocket for this drug
$0
Persistent skin or muscle disease despite steroid + steroid-sparing agent
Step 3: For persistent disease, you're prescribed IVIG (Octagam 10%)
2.0 g/kg every 4 weeks — the first and only FDA-approved therapy specifically for dermatomyositis (2021)
What your doctor says
"Since you're still struggling despite steroids and a steroid-sparing agent, we can now use IVIG. It's the first drug ever formally approved for dermatomyositis, based on a real placebo-controlled trial."
79% of patients respond vs. 44% on sugar pill respond at week 163
Blood-clotting events occurred in 6 patients on IVIG in the pivotal ProDerm study3
Median time to response: 35 days
Annual cost before insurance ~$80,000–$130,000
How long were you on this?
What happened?
Your coinsurance for this drug
Your estimated annual out-of-pocket for this drug
$0
For non-responders to standard treatment, Rising Cancer Risk & Multi-Organ Damage
Interstitial lung disease, treatment-resistant weakness, and an elevated malignancy risk that standard therapy doesn't screen for on its own
What Your Doctor says
"Your muscle strength has plateaued despite everything we've tried. We should also make sure you're up to date on cancer screening, since dermatomyositis carries an associated malignancy risk."
22% relapse rate reported after treatment withdrawal6
No FDA-approved therapy existed at all until 20212
79%
IVIG responder rate in the pivotal ProDERM trial3
44%
Placebo responder rate in the same trial3
60–80%
Historical 5-year survival range for PM/DM4
35 days
Median time to IVIG response7
ProDERM trial results at Week 16
Octagam 10% (IVIG) responders 78.7%
Placebo responders 43.8%
At least moderate improvement (TIS ≥40) on IVIG 68%
Major improvement (TIS ≥60) on IVIG 32%
What refractory or advanced disease actually involves
⏳ Until 2021, there was no approved drug at all. Every therapy for dermatomyositis — steroids, methotrexate, azathioprine, even IVIG before its approval — was used off-label, extrapolated from small trials or decades-old case series, until the ProDERM trial finally established a formal evidence base.2
🫁 Interstitial lung disease and malignancy both ride along with the muscle disease. PM/DM carries meaningful associations with underlying malignancy and interstitial lung disease, both of which require separate, ongoing screening that standard myositis follow-up doesn't automatically include.
💉 Even the newest approved therapy carries real risk. In the pivotal ProDERM trial, thromboembolic events occurred in patients receiving IVIG, prompting a reduced maximum infusion rate — a reminder that this population is already at elevated clotting risk.3
📉 Survival estimates reflect a genuinely serious disease. Historical 5-year survival estimates of 60–80% for PM/DM reflect not just muscle weakness but the cumulative impact of lung disease, cardiac involvement, aspiration risk, and malignancy.4
⚠ A real drug approval doesn't erase decades of an evidence gap
IVIG's 2021 approval was a genuine breakthrough — the first randomized, placebo-controlled proof that a specific dermatomyositis therapy works. But it followed decades where every other treatment decision was made without that level of evidence, and many refractory patients still fall outside what any approved therapy can fully address.

What dermatomyositis/polymyositis is really costing you

Proximal muscle weakness directly affects the physical tasks most jobs require — climbing stairs, lifting, even rising from a chair. That functional impact, plus the rash and fatigue, adds up well beyond the drug bill.

Based on your journey above–adjust the numbers to match your situation.
Work days affected by weakness/rash/fatigue in the last 12 months
Your hourly wage (for lost income calculation)
Your estimated total annual cost of myositis $0
Drug out-of-pocket costs $0
Lost income (missed days) $0
Reduced productivity at work (presenteeism) $0
Proximal muscle weakness directly limits physical job tasks even on days formally “worked”
If your care reaches the last phase of this journey — IVIG (Octagam 10%)
$0
Projected patient out-of-pocket for a full year at that phase, at your coinsurance selection for it above (or a typical default if you haven't reached it yet)
The Other Side of the Bill

What your insurer is paying

Steroids and steroid-sparing agents are inexpensive generics — but IVIG, the only FDA-approved dermatomyositis therapy, is one of the most expensive infused products in autoimmune medicine.

Annual Payer Perspective — Commercial Insurance
What your health plan spends on your myositis each year
Based on your treatment journey above · All figures reflect payer (insurer) paid portion, not patient out-of-pocket cost.
Estimated annual payer cost for your myositis care $0
Immunosuppressant / IVIG drug spend (payer portion)
~80% of net price after patient coinsurance; IVIG alone can exceed $100,000/year at full dosing
$0
Medical costs (rheumatology, infusion administration, malignancy/ILD screening)
Includes periodic cancer screening and pulmonary function testing associated with PM/DM
~$7,500
Have you relapsed, or been evaluated for lung/cancer involvement, in the last 12 months?
Malignancy and interstitial lung disease workups are a recurring, often underappreciated cost center in myositis care
IVIG, the only FDA-approved dermatomyositis therapy, can cost $80,000–$130,000/year at full dosing — among the highest per-patient drug costs on this site.
Payer cost projection if care reaches the last phase of this journey — IVIG (Octagam 10%)
$0
Estimated annual payer spend at that phase: ~80% of drug price plus baseline medical costs, excluding any flare/crisis event above
⚑ The cost of decades without a real evidence base
Because every therapy besides IVIG was adopted without placebo-controlled trials, dosing and duration decisions have historically been driven by expert consensus rather than data — which can mean longer, less targeted treatment courses (and cost) than a disease with a fuller evidence base might otherwise require.
Understanding Your Risk

What the research shows over time

These outcomes are not inevitable — but they are the documented range of what happens across the myositis treatment ladder, including for patients now able to access IVIG.

Based on peer-reviewed clinical data
Long-term outcomes for myositis patients on today's standard of care
💊
78.7% of patients responded to IVIG (Octagam 10%) at week 16 in the pivotal ProDERM trial, vs. 43.8% on placebo3
🔁
22% relapse rate reported after treatment withdrawal in one long-term follow-up cohort6
📉
60–80% historical 5-year survival range for polymyositis/dermatomyositis, reflecting lung, cardiac, and malignancy-related risk4
🧬
2021 was the year the first-ever FDA-approved dermatomyositis therapy arrived — decades after the disease was first described2
✦ A different journey exists

Thymos Health offers another way

Conventional myositis care focuses on managing symptoms through sequential medications. Thymos goes further – synthesizing diagnostics, medical history, symptoms, and lifestyle to understand what's driving your disease and customizes care based on your individual needs.

✓
Root cause treatment — not just another layer of suppression
✓
Whole system autoimmune specialist quarterbacks your labs, your team, your care plan
✓
24/7 personalized support — not just at your next follow-up in 3 months
✓
80%+ symptom relief within 3 months across autoimmune conditions
No commitment. Takes 2 minutes.
Sources & Citations ▼
[1] Dermatomyositis. American Family Physician, 2001, and Pharmacological Strategies in Dermatomyositis: Current Treatments and Future Directions, PMC, 2024. Dermatomyositis prevalence estimated at 1–10 cases per million adults; global annual incidence 1–2 per 100,000 and rising.
Source: aafp.org
[2] ProDERM study results of octagam 10% treatment in patients with dermatomyositis published in NEJM. Octapharma press release, 2022. Prior to the ProDERM study, no therapy had been approved in the US or Europe for dermatomyositis based on randomized clinical trial evidence; Octagam 10% was approved by the FDA in 2021 on this basis.
Source: octapharma.com
[3] Trial of Intravenous Immune Globulin in Dermatomyositis (ProDERM). New England Journal of Medicine, 2022 (n=95). Responder rate 78.7% (IVIG) vs. 43.8% (placebo) at week 16; thromboembolic events occurred in patients on IVIG, prompting a reduced maximum infusion rate.
Source: nejm.org
[4] Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate and azathioprine. PMC. 5-year survival estimates for PM/DM historically range from 60% to 80%; younger age, female sex, and Caucasian race independently predicted better long-term survival.
PMC: PMC3392815
[5] Therapy of polymyositis and dermatomyositis. ScienceDirect, 2011. High-dose oral prednisone (1mg/kg/day) is the mainstay first-line therapy for PM/DM, adopted from case-series-level evidence rather than placebo-controlled trials.
Source: sciencedirect.com
[6] Clinical, electrophysiologic, and histopathologic profile, and outcome in idiopathic inflammatory myositis: An analysis of 68 cases. PMC. Prednisolone ± azathioprine was the initial treatment in the large majority of cases; relapse with drug withdrawal occurred in 22% of patients, with 70% overall favorable outcome and 16% mortality in this cohort.
PMC: PMC3021927
[7] Intravenous Immunoglobulin for the Treatment of Adult Dermatomyositis. Rare Disease Advisor, 2025, summarizing the ProDERM trial. Median time to IVIG response was 35 days, with a clinical response rate approaching 80%.
Source: rarediseaseadvisor.com